Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK1101 in advanced solid tumors
NCT07139067Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YK1101 in solid tumor (advanced stage), sponsored by Peking University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment related Adverse Events at 28 days. Started Apr 2025; status: recruiting.
02
Drugs
YK1101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07139067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139067.